Quantitative Proteomic Analysis Reveals That Luks-Pv Exerts Antitumor Activity by Regulating the Key Proteins and Metabolic Pathways in HepG2 Cells
Anti-Cancer Drugs - United States
doi 10.1097/cad.0000000000000866
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2020
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)